Alimera’s Iluvien Suffers Same Demise As Lucentis; NICE Rejects For DME
Executive Summary
Triumphant in Europe at the regulatory stage, Alimera finds that health technology assessment is a different ball game, as NICE turns down Iluvien for diabetic macular edema on two counts.